Study of Hydrogen Inhalation Compared With Placebo in Type 2 Diabetes Patients

Type 2 Diabetes Clinical Trial

Official title:

Efficacy and Safety of Hydrogen Inhalation in Subjects With Type 2 Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05842993
• Other study ID #: QDU-HD-2023/1732
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: October 10, 2023

Study information

• Verified date: May 2023
• Source: Qingdao University
• Contact: Tongshang Ni, Ph.D
• Phone: +86 17354605382
• Email: neetongshang[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of hydrogen inhalation in type 2 diabetes patients.

Description:

The objective of the study is to evaluate the efficacy and safety of hydrogen inhalation compared with placebo in patients with type 2 diabetes mellitus after 12-week treatment in a randomized, double-blind, placebo-controlled design.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: October 10, 2023
• Est. primary completion date: October 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Aged 18-75 years old and gender of both sex;

2. Body mass index 18.5kg/m2 to 40 kg/m2;

3. Diagnosed as type 2 diabetes according to the diagnostic criteria of type 2 diabetes established by WHO in 1999;

4. Patients with type 2 diabetes whose blood glucose is not well controlled after diet control and exercise therapy for more than 3 months;

5. HbA1c 7% to 10%, and fasting venous plasma glucose = 15 mmol/L;

6. Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the informed consent.

Exclusion Criteria:

1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;

2. Screening for having received anti-diabetic drug therapy within 3 months or receiving continuous anti-diabetic drug therapy at any time before screening for more than 3 months;

3. History of diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome, lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;

4. Hyperlipidemia patients with irregular or unstable dose of lipid-lowering drugs

5. Chronic gastrointestinal disorders with obvious digestive and absorption disorders, as well as other endocrine diseases, such as hyperthyroidism, hypercortisolism, acromegaly, etc.;

6. Patients with diseases that may worsen due to intestinal flatulence (such as Roemheld syndrome, severe hernia, intestinal obstruction, intestinal surgery and intestinal ulcers);

7. Had transient ischemic attack, cerebrovascular accident or unstable angina in the past 6 months; History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;

8. Subjects (taking or not taking antihypertensive drugs) had poor blood pressure control (SBP = 160mmhg, or DBP = 100mmhg);

9. liver disease, ALT or AST > 2 ULN, or TBIL > 2 ULN, and the diagnosis was confirmed within one week;

10. Patients with renal function impairment (Cr > 1 ULN or Ccr < 60ml / min) and confirmed by reexamination within one week;

11. Had malignancy in the past 5 years, not including basal cell carcinoma;

12. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);

13. Combined use of drugs that affect glucose metabolism, such as glucocorticoids;

14. Combined use of Chinese herbal medicine with the effect of regulating blood glucose within 3 months;

15. Those who have serious diseases and may be in danger of life during treatment and follow-up;

16. Mental and neurological disorders, unable to correctly express their wishes;

17. Alcoholics and drug abusers and addicts;

18. Women of childbearing age are pregnant, breastfeeding, have pregnancy intentions or have a positive pregnancy test (urine HCG or blood HCG), and should not take effective contraceptive measures during the trial (effective contraceptive measures include sterilization, intrauterine device, oral contraceptive or diaphragm method prescribed by local law);

19. Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months;

20. Patients with other diseases that the researchers believe will not be able to evaluate or are unlikely to complete the expected course of treatment and follow-up.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Respiratory Aspiration
• Type 2 Diabetes

Intervention

Device:
• Hydrogen generator
Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
• Analogue machine
Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.

Locations

Country	Name	City	State
China	Qingdao Traditional Chinese Medicine Hospital	Qingdao	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Qingdao University	Qingdao Hiser Medical Group

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in glycosylated hemoglobin (HbA1c)	The change in HbA1c from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in fasting plasma glucose (FPG)	The change in FPG from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in 2h-postprandial plasma glucose (2h-PPG)	The change in 2h-PPG from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Patients with HbA1c <7.0%	Percentage of patients reaching HbA1c <7% at Week 12	At Week 12
Secondary	Patients with HbA1c <6.5%	Percentage of patients reaching HbA1c <6.5% at Week 12	At Week 12
Secondary	Change in fasting plasma insulin	The change in fasting plasma insulin from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in insulin sensitivity and beta cell function assessed by the homeostatic model assessment (HOMA)	The change in HOMA-IR and HOMA-ß from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in serum lipid profile	The change in total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in waist circumference	The change in waist circumference from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in body weight	The change in body weight from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in body mass index (BMI)	The change in BMI from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in blood pressure	The change in blood pressure from baseline to Week 12 in hydrogen inhalation group compared to Placebo.	Baseline and Week 12
Secondary	Change in oxidative stress index and inflammatory index	Serum MDA and SOD, TNF-a, IL-6 quantifications were conducted using commercial kits from baseline to Week 12.	Baseline and Week 12
Secondary	Safety measurement	The incidence rates of adverse events, clinical findings in the physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory tests (hematology, blood biochemistry, and urinalysis) from baseline to Week 12.	Baseline to Week 12